Drug Titration Patterns and HbA 1c Levels in Type 2 Diabetes

Overview

Journal Int J Clin Pract

Publisher Wiley

Specialty General Medicine

Date 2009 Jul 3

PMID 19570118

Citations 2

Authors

J Ross Maclean

R H Chapman

C P Ferrufino

G Krishnarajah

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate oral antidiabetes drug (OAD) use, haemoglobin A(1c) (HbA(1c)) testing and glycaemic control in type 2 diabetes patients.

Study Design: Retrospective analysis based on claims data from the Integrated Healthcare Information Services (IHCIS) National Managed Care Benchmark Database.

Methods: OAD use and HbA(1c) testing were analysed for patients with >or= 2 claims indicating diagnosis of type 2 diabetes and >or= 1 90-day OAD treatment period between 1 January, 2000 and 30 June, 2006. Likelihood of HbA(1c) testing was examined using multivariable logistic regression analyses, adjusting for OAD regimen and patients' sociodemographical characteristics.

Results: Patients were classified based on initial OAD regimen: metformin (MET) (n = 22,203; 41.3%), sulphonylurea (SFU) (n = 18,439; 34.3%), thiazolidinedione (TZD) (n = 7663; 14.3%), SFU + MET (n = 5467; 10.2%) and TZD + MET (n = 2355; 4.2%). A total of 51.5% of patients had HbA(1c) testing during 90 days preceding OAD initiation through regimen completion. Approximately, 65% of MET and 58% of SFU patients had no titration of initial regimen. Patients demonstrating inadequate glucose control decreased from 68.5% at baseline to 46.9% within 90 days of regimen initiation. Multivariable logistic regression indicated several negative predictors of HbA(1c) testing, including SFU use, age 65+ years, moderate insurance copayment and preindex inpatient utilisation. Multivariable logistic regression of variables associated with reduced likelihood of up-titration included TZD, SFU + MET, or TZD + MET treatment, age 18-34 years, Medicare insurance and any preindex healthcare utilisation.

Conclusions: Patients are not being transitioned to additional OADs in a stepwise fashion and/or are receiving inadequate titration on current OAD regimens. The low rate of HbA(1c) testing and rates of control are contributing factors.

Citing Articles

Dual Therapy Appears Superior to Monotherapy for Low-Income Individuals With Newly Diagnosed Type 2 Diabetes.

Vaughan E, Johnston C, Hyman D, Hernandez D, Hemmige V, Foreyt J J Prim Care Community Health. 2017; 8(4):305-311.

PMID: 29216790 PMC: 5748290. DOI: 10.1177/2150131917745760.

Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study.

Roumie C, Greevy R, Grijalva C, Hung A, Liu X, Griffin M BMC Endocr Disord. 2016; 16(1):32.

PMID: 27255309 PMC: 4890276. DOI: 10.1186/s12902-016-0101-2.

References

. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2002; 25(1):213-29. DOI: 10.2337/diacare.25.1.213. View

Nau D . Evaluating medication use for continuous quality improvement in diabetes care. J Manag Care Pharm. 2003; 8(5):378-82. DOI: 10.18553/jmcp.2002.8.5.378. View

Coberley C, McGinnis M, Orr P, Coberley S, Hobgood A, Hamar B . Association between frequency of telephonic contact and clinical testing for a large, geographically diverse diabetes disease management population. Dis Manag. 2007; 10(2):101-9. DOI: 10.1089/dis.2006.632. View

Saydah S, Fradkin J, Cowie C . Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004; 291(3):335-42. DOI: 10.1001/jama.291.3.335. View

Parchman M, Pugh J, Romero R, Bowers K . Competing demands or clinical inertia: the case of elevated glycosylated hemoglobin. Ann Fam Med. 2007; 5(3):196-201. PMC: 1886492. DOI: 10.1370/afm.679. View

Rodbard H, Blonde L, Braithwaite S, Brett E, Cobin R, Handelsman Y . American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007; 13 Suppl 1:1-68. DOI: 10.4158/EP.13.S1.1. View

Riddle M . Oral pharmacologic management of type 2 diabetes. Am Fam Physician. 1999; 60(9):2613-20. View

. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995; 44(11):1249-58. View

Nichols G, Koo Y, Shah S . Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J Gen Intern Med. 2007; 22(4):453-8. PMC: 1829438. DOI: 10.1007/s11606-007-0139-y. View

10.

Lawrence D, Ragucci K, Long L, Parris B, Helfer L . Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm. 2006; 12(6):466-71. PMC: 10437554. DOI: 10.18553/jmcp.2006.12.6.466. View

11.

Riddle M . Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am. 2005; 34(1):77-98. DOI: 10.1016/j.ecl.2004.12.002. View

12.

Nichols G, Glauber H, Javor K, Brown J . Achieving further glycemic control in type 2 diabetes mellitus. West J Med. 2000; 173(3):175-9. PMC: 1071057. DOI: 10.1136/ewjm.173.3.175. View

13.

Karter A, Moffet H, Liu J, Parker M, Ahmed A, Go A . Glycemic response to newly initiated diabetes therapies. Am J Manag Care. 2007; 13(11):598-606. PMC: 2213629. View

14.

Thomas K, Thomas M, Stroebel R, McDonald F, Hanson G, Naessens J . Use of a registry-generated audit, feedback, and patient reminder intervention in an internal medicine resident clinic--a randomized trial. J Gen Intern Med. 2007; 22(12):1740-4. PMC: 2219846. DOI: 10.1007/s11606-007-0431-x. View

15.

Hertz R, Unger A, Lustik M . Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther. 2005; 27(7):1064-73. DOI: 10.1016/j.clinthera.2005.07.009. View

16.

Sheehan M . Current therapeutic options in type 2 diabetes mellitus: a practical approach. Clin Med Res. 2005; 1(3):189-200. PMC: 1069045. DOI: 10.3121/cmr.1.3.189. View

17.

Brown J, Nichols G, Perry A . The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004; 27(7):1535-40. DOI: 10.2337/diacare.27.7.1535. View

18.

. Standards of medical care in diabetes--2008. Diabetes Care. 2008; 31 Suppl 1:S12-54. DOI: 10.2337/dc08-S012. View

19.

Riedel A, Heien H, Wogen J, Plauschinat C . Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy. 2007; 27(8):1102-10. DOI: 10.1592/phco.27.8.1102. View

20.

Jellinger P, Davidson J, Blonde L, Einhorn D, Grunberger G, Handelsman Y . Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract. 2007; 13(3):260-8. DOI: 10.4158/EP.13.3.260. View